We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Metacrine, Inc. (“Metacrine” or the “Company”) (NASDAQ:MTCR), in connection with the acquisition of the Company by Equillium, Inc. (“Equillium”)(NASDAQ: EQ).  Under the terms of the merger agreement, Equillium will issue stock valued at a 25% premium over the net cash delivered at closing, which is estimated to be approximately $26 million.

Weiss Law is investigating whether (i) Metacrine’s board of directors acted in the best interests of Company shareholders in agreeing to the merger, (ii) the merger consideration adequately compensates Metacrine’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.